KR101413613B1 - 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 - Google Patents

약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 Download PDF

Info

Publication number
KR101413613B1
KR101413613B1 KR1020087021036A KR20087021036A KR101413613B1 KR 101413613 B1 KR101413613 B1 KR 101413613B1 KR 1020087021036 A KR1020087021036 A KR 1020087021036A KR 20087021036 A KR20087021036 A KR 20087021036A KR 101413613 B1 KR101413613 B1 KR 101413613B1
Authority
KR
South Korea
Prior art keywords
organic acid
acid
beads
tpr
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087021036A
Other languages
English (en)
Korean (ko)
Other versions
KR20080098627A (ko
Inventor
고피 엠 벤카테쉬
진왕 레이
네할 에이치 브야스
Original Assignee
앱탈리스 파마테크, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앱탈리스 파마테크, 인코포레이티드 filed Critical 앱탈리스 파마테크, 인코포레이티드
Publication of KR20080098627A publication Critical patent/KR20080098627A/ko
Application granted granted Critical
Publication of KR101413613B1 publication Critical patent/KR101413613B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087021036A 2006-01-27 2007-01-29 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 Expired - Fee Related KR101413613B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76275006P 2006-01-27 2006-01-27
US60/762,750 2006-01-27
PCT/US2007/061217 WO2007090082A2 (en) 2006-01-27 2007-01-29 Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids

Publications (2)

Publication Number Publication Date
KR20080098627A KR20080098627A (ko) 2008-11-11
KR101413613B1 true KR101413613B1 (ko) 2014-07-10

Family

ID=38325269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087021036A Expired - Fee Related KR101413613B1 (ko) 2006-01-27 2007-01-29 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템

Country Status (14)

Country Link
US (1) US20070190145A1 (enExample)
EP (2) EP2363117B1 (enExample)
JP (3) JP5433236B2 (enExample)
KR (1) KR101413613B1 (enExample)
CN (2) CN103211779B (enExample)
AU (1) AU2007211091B8 (enExample)
BR (1) BRPI0707324A2 (enExample)
CA (1) CA2640460C (enExample)
ES (2) ES2550035T3 (enExample)
IL (1) IL193020A0 (enExample)
NZ (1) NZ570039A (enExample)
RU (1) RU2490012C2 (enExample)
WO (1) WO2007090082A2 (enExample)
ZA (1) ZA200806497B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
BRPI0820997A2 (pt) * 2007-12-10 2014-12-23 Eurand Inc Comprimidos de desintegração oral compreendendo difenidramina.
BRPI0821761A2 (pt) * 2007-12-21 2015-06-16 Eurand Inc Composições de comprimidos de desintegração oral de temazepam
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20110172249A1 (en) * 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
JP2012518655A (ja) * 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド プロトンポンプ阻害剤を含む制御放出組成物
WO2010118232A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
MX337603B (es) 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN106061292B (zh) * 2013-12-16 2020-01-21 麻省理工学院 强化的微量营养素盐调配物
SG11201607511WA (en) 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CN106999436B (zh) * 2014-10-01 2021-07-02 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
RU2719416C2 (ru) * 2014-10-01 2020-04-17 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
CN104473895A (zh) * 2014-11-20 2015-04-01 美吉斯制药（厦门）有限公司 拉莫三嗪口腔崩解缓释片
US10406336B2 (en) * 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108624005B (zh) * 2017-03-24 2021-10-29 华东理工大学 基于poc和介孔纳米微球的双因子缓释系统
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
EP4333646A2 (en) * 2021-05-03 2024-03-13 Cambridge Glycoscience Ltd Soluble and insoluble saccharide compositions and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950009098B1 (en) * 1986-08-13 1995-08-14 Thomae Gmbh Dr K Pharmaceutical composition for use in treating clot formation
KR20040084890A (ko) * 2001-10-04 2004-10-06 유란드 파마슈티칼스 리미티드 프로프라놀롤의 시한적인 지속 방출성 다중-과립형 투여형태

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
US4381546A (en) * 1979-03-02 1983-04-26 Paradyne Corporation System for the quantitative measurement of impairments in the communication channel of a quadrature amplitude modulation data communication system
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
EP1058538B9 (en) * 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
KR20020072290A (ko) * 2000-01-20 2002-09-14 델시스 파머수티컬 코포레이션 다단계 약물 투여 형태
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
SK6182003A3 (en) * 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof
ATE508725T1 (de) * 2001-06-20 2011-05-15 Takeda Pharmaceutical Verfahren zur herstellung von tabletten
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
EP1970055B1 (en) * 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950009098B1 (en) * 1986-08-13 1995-08-14 Thomae Gmbh Dr K Pharmaceutical composition for use in treating clot formation
KR20040084890A (ko) * 2001-10-04 2004-10-06 유란드 파마슈티칼스 리미티드 프로프라놀롤의 시한적인 지속 방출성 다중-과립형 투여형태

Also Published As

Publication number Publication date
WO2007090082A2 (en) 2007-08-09
EP2363117B1 (en) 2015-08-19
JP5433236B2 (ja) 2014-03-05
RU2008134912A (ru) 2010-03-10
EP2363117A1 (en) 2011-09-07
EP1976491A2 (en) 2008-10-08
BRPI0707324A2 (pt) 2011-05-03
CA2640460C (en) 2015-05-26
IL193020A0 (en) 2009-09-22
WO2007090082A3 (en) 2007-12-21
ZA200806497B (en) 2009-12-30
AU2007211091B8 (en) 2013-08-29
NZ570039A (en) 2011-07-29
JP2013249305A (ja) 2013-12-12
CN103211779A (zh) 2013-07-24
CN101410094B (zh) 2013-04-17
CN103211779B (zh) 2016-03-16
KR20080098627A (ko) 2008-11-11
US20070190145A1 (en) 2007-08-16
ES2531215T3 (es) 2015-03-11
JP5918179B2 (ja) 2016-05-18
CA2640460A1 (en) 2007-08-09
JP2016014048A (ja) 2016-01-28
EP1976491B1 (en) 2014-12-17
ES2550035T3 (es) 2015-11-04
AU2007211091B2 (en) 2013-05-02
AU2007211091A8 (en) 2013-08-29
AU2007211091A1 (en) 2007-08-09
CN101410094A (zh) 2009-04-15
JP2009524697A (ja) 2009-07-02
RU2490012C2 (ru) 2013-08-20

Similar Documents

Publication Publication Date Title
KR101489401B1 (ko) 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
JP5433236B2 (ja) 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20090232885A1 (en) Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
CN102006862A (zh) 包括弱碱性药物的组合物和控释剂型
US20110135724A1 (en) Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting
AU2013204408B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
AU2013204400B2 (en) Drug delivery systems comprising weakly basic drugs and organic acids
HK1161695A (en) Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
MX2008009616A (en) Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170613

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180612

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190625

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190625